Table 3 : Eicosanoids in asthmatic patients at baseline and following histamine challenge in the subgroups.

  AIA ATA p-value
baseline challenge baseline challenge I II III
LTB4 50.37 44.16 39.53 30.66 0.39 0.74 0.90
[pg/mL] (38.39-97.38) (24.37-59.99) (25.11-55.28) (11.44-47.89)
LTB4 83.00 78.53 71.11 60.56 0.56 0.93 1.00
[pg/µg of PA] (62.88-173.98) (42.01-119.02) (54.81-94.13) (30.56-120.39)
CysLTs 7.68 4.57 4.67 4.48 0.01* 0.07 0.99
[pg/mL] (5.62-14.46) (4.2-6.42) (3.52-5.44) (3.04-6.5)
CysLTs 13.72 9.85 8.46 8.6 0.02* 0.13 0.63
[pg/µg of PA] (9.55-19.94) 4.97-11.45) (6.19-10.66) (7.23-11.63)
LTC4 2.24 0.87 1.22 1.39 0.003* 0.001* 1.00
[pg/mL] (1.90-5.19) (0.54-1.43) (0.91-1.44) (0.76-1.77)
LTC4 3.68 1.83 2.15 2.60 0.01* 0.002* 0.88
[pg/µg of PA] (3.32-6.62) (0.83-2.26) (1.69-2.61) (1.89-3.71)
trans-LTC4 2.93 0.54 0.88 1.10 0.19 0.001* 0.83
[pg/mL] lg (0.60-4.72) (0.48-0.62) (0.74-1.37) (0.60-1.52)
trans-LTC4 4.81 0.85 2.01 2.27 0.19 0.001* 0.97
[pg/µg of PA] (1.07-5.88) (0.62-1.36) (1.47-2.60) (1.62-2.94)
LTD4 1.19 1.12 0.96 0.80 0.59 1.00 1.00
[pg/mL] (0.88-1.65) (0.83-1.76) (0.75-1.15) (0.72-1.07)
LTD4 1.80 1.84 1.96 1.42 0.91 0.99 0.99
[pg/µg of PA] (1.12-2.94) (1.28-2.72) (0.92-2.25) (1.20-2.16)
LTE4 4.18 2.80 2.31 1.79 0.22 0.58 0.97
[pg/mL] (3.18-7.62) (2.21-3.40) (1.49-2.86) (1.48-4.11)
LTE4 6.74 6.08 4.08 4.32 0.42 0.73 1.00
[pg/µg of PA] (5.22-9.50) (2.58-6.74) (3.17-5.79) (3.09-5.93)
PGE2 3.22 2.84 1.58 1.58 0.004* 0.96 1.00
[pg/mL] (2.23-4.13) (2.21-7.89) (1.24-1.94) (1.15-2.00)
PGE2 4.90 5.04 2.76 3.68 0.04* 0.80 0.90
[pg/µg of PA] (3.66-7.08) (4.11-11.56) (2.29-3.29) (2.33-4.34)
13,14-dihydro-15-keto-PGE2 3.82 3.83 2.73 3.46 0.83 0.91 1.00
[pg/mL] (3.49-4.88) (2.96-4.35) (2.26-5.65) (2.50-5.41)
13,14-dihydro-15-keto-PGE2 6.55 6.34 4.64 6.22 1.00 1.00 0.88
[pg/µg of PA] (4.65-8.03) (3.81-8.73) (3.32-15.98) (4.77-15.88)      
tetranor-PGE-M 22.88 8.80 12.36 20.79 0.41 0.02* 0.23
[pg/mL] (16.87-38.80) (8.39-11.14) (7.97-38.89) (15.76-32.78)      
tetranor-PGE-M 36.64 14.56 33.41 41.25 0.73 0.04* 0.10
[pg/µg of PA] (28.50-49.50) (13.00-19.42) (10.92-51.85) (27.64-87.07)      
PGD2 1.48 1.48 1.58 1.23 0.99 0.99 0.90
[pg/mL] (1.29-1.77) (1.20-2.36) (1.28-1.86) (0.84-1.85)      
PGD2 2.52 2.29 2.04 1.98 0.99 0.86 1.00
[pg/µg of PA] (1.89-3.03) (1.99-5.19) (1.76-4.80) (1.64-3.49)      
13,14-dihydro-15-keto-PGD2 5.03 4.81 2.91 2.92 0.24 0.93 0.99
[pg/mL] (4.19-5.63) (3.52-4.92) (1.95-3.48) (2.16-4.21)      
13,14-dihydro-15-keto-PGD2 7.18 6.64 4.97 5.88 0.82 1.00 0.67
[pg/µg of PA] (6.27-9.33) (5.44-9.86) (4.04-7.44) (3.90-8.71)      
9a,11b-PGF2 0.22 0.10 0.16 0.12 0.88 0.91 0.52
[pg/mL] (GC-MS) (0.14-0.38) (0.08-0.71) (0.09-0.28) (0.09-0.14)      
9a,11b-PGF2 0.30 0.20 0.24 0.23 0.99 0.99 0.85
[pg/µg of PA] (GC-MS) (0.25-0.65) (0.14-1.23) (0.18-0.70) (0.16-0.39)      
15-deoxy-delta12,14-PGJ2 5.55 3.30 2.55 2.84 0.04* 0.43 0.41
[pg/mL] (4.24-8.36) (2.12-4.98) (1.43-3.58) (2.34-5.02)      
15-deoxy-delta12,14-PGJ2 9.13 5.40 4.58 7.11 0.09 0.73 0.32
[pg/µg of PA] (5.28-10.66) (3.66-8.33) (2.52-5.84) (5.51-8.13)      

* statistical significance values are expressed as median with upper and lower quartile [25%-75% percentiles].
AIA: aspirin-induced asthma, ATA: aspirin-tolerant asthma, CysLTs: cysteinyl leukotrienes,
GC-MS: gas chromatography/mass spectrometry, LT: leukotriene, PA: palmitic acid, PG: prostaglandin.
p-values :
I - AIA vs ATA at baseline.
II – AIA at baseline vs AIA post challenge.
III – ATA at baseline vs ATA post challenge.

Kaszuba et al.Hypersensitivity  2013 1:4DOI : 10.7243/2052-594X-1-4